Johnson & Johnson
As of the edition of 20 October 2026, Johnson & Johnson runs 362 drugs, 145 of them marketed; it is on route A at 32 targets and on route B at 64 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 123 company names in this family.
- Tibotec BVBA: acquired in 2002; successor Johnson & Johnson
- Tibotec Pharmaceuticals, Ireland: acquired in 2002; successor Johnson & Johnson
- Ortho Mcneil Pharmaceutical: merged in 2011; successor ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC
- ORTHO MCNEIL JANSSEN PHARMACEUTICALS INC: renamed in 2013
- Actelion Pharmaceuticals Ltd: acquired in 2017
- Actelion Pharmaceuticals Us Inc: acquired in 2017; successor Johnson & Johnson
- Janssen Infectious Diseases BVBA: renamed in 2020
- Momenta Pharmaceuticals, Inc.: acquired in 2020
- Abiomed, Inc.: acquired in 2022; successor Johnson & Johnson
- Shockwave Medical, Inc.: acquired in 2024; successor Johnson & Johnson
- INTRA-CELLULAR THERAPIES INC: acquired in 2025
- Taris Biomedical LLC: merged in 2026; successor Janssen Biotech, Inc.
And 3 more.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 145 |
| Active | 62 |
| Went quiet | 76 |
| Stopped | 58 |
| Withdrawn from market | 1 |
| Status not established | 20 |
| Total | 362 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Gemcitabine | none listed | 1 |
| Doxorubicin | none listed | 3 |
| Metformin | none listed | 4 |
| Bortezomib | none listed | 1 |
| Acetaminophen | none listed | 17 |
| Fentanyl | none listed | 6 |
| Ibuprofen | none listed | 11 |
| Nicotine | none listed | 1 |
| Decitabine | none listed | 4 |
| Itraconazole | none listed | 0 |
| Rivaroxaban | none listed | 2 |
| Sodium chloride | none listed | 0 |
| Ibrutinib | Ends 2033 (patent) | 2 |
| Daratumumab | Ends 2028 (orphan exclusivity) | 1 |
| Infliximab | Ended 2018 (orphan exclusivity) | 3 |
| Emtricitabine | Ends 2032 (patent) | 0 |
| Risperidone | none listed | 2 |
| Methylphenidate | none listed | 11 |
| Leuprolide | Ended 2026 (exclusivity) | 1 |
| Remifentanil | none listed | 1 |
| Epoetin alfa | Ended 2001 (computed from the first US licence) | 1 |
| Esketamine | Ends 2028 (exclusivity) | 5 |
| Progesterone | none listed | 3 |
| Estradiol | Ends 2032 (patent) | 6 |
| Metronidazole | none listed | 0 |
A route B row is one company at one target. 120 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 32 targets, route B at 64 targets.
All 96 rows on route A or B
In the product96 company-target rows on route A or B; 93 are not shown here, and no score is.
See all 96 targets where Johnson & Johnson needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 307 trials led
- Cancer: 285 trials led
- Immune system: 255 trials led